BridgeBio real-world study shows Attruby cuts ATTR-CM clinical worsening risk 34% vs Pfizer’s tafamidis
Bitget2026/09/23 11:47- BridgeBio reported peer-reviewed real-world study results in Cardiology and Therapy comparing its ATTR-CM drug Attruby to Pfizer’s tafamidis.
- Claims-data analysis found Attruby patients were less likely to show early clinical worsening than those starting tafamidis.
- Benefits appeared within weeks, supporting a potential argument for frontline use or switching from tafamidis in routine practice.
- Separate electronic health record-based comparative study is slated for release at a 2026 medical meeting.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
